In a preliminary study of men with type 2 diabetes, the use of phosphodiesterase type-5 (PDE5) inhibitors was associated with reduced all-cause mortality, even in men who had a previous myocardial infarction (MI), during a 5-year follow-up.
A second study, with a few of the same coauthors, came...